Sanara Medtech Inc
NASDAQ:SMTI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
26.86
41.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sanara Medtech Inc
Cash from Operating Activities
Sanara Medtech Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Sanara Medtech Inc
NASDAQ:SMTI
|
Cash from Operating Activities
-$1.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
||
Haemonetics Corp
NYSE:HAE
|
Cash from Operating Activities
$85m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
||
ICU Medical Inc
NASDAQ:ICUI
|
Cash from Operating Activities
$255.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
||
Align Technology Inc
NASDAQ:ALGN
|
Cash from Operating Activities
$522.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
||
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cash from Operating Activities
$499.3m
|
CAGR 3-Years
131%
|
CAGR 5-Years
46%
|
CAGR 10-Years
46%
|
||
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cash from Operating Activities
$214.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
24%
|
CAGR 10-Years
16%
|
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
See Also
What is Sanara Medtech Inc's Cash from Operating Activities?
Cash from Operating Activities
-1.8m
USD
Based on the financial report for Sep 30, 2024, Sanara Medtech Inc's Cash from Operating Activities amounts to -1.8m USD.
What is Sanara Medtech Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
1%
Over the last year, the Cash from Operating Activities growth was 41%. The average annual Cash from Operating Activities growth rates for Sanara Medtech Inc have been 21% over the past three years , -8% over the past five years , and 1% over the past ten years .